光热治疗
纳米载体
材料科学
纳米技术
纳米颗粒
癌症治疗
体内
药物输送
胶体金
热稳定性
联合疗法
癌症
化学
药理学
有机化学
医学
生物
生物技术
内科学
作者
Yinglan Yu,Jun Zhang,Wan Huang,Luo Li,Han Li,Taolei Sun
标识
DOI:10.1016/j.actbio.2023.12.030
摘要
High efficiency and spatio-temporal control remains a challenge for multi-modal synergistic cancer therapy. Herein, based on gold nanoparticles (AuNPs) and zeolite-like imidazole skeleton material (ZIF-8), a spatio-temporal controllable photothermal/ chemical dynamic/ chemotherapy three modal synergistic anti-tumor nano-carrier (HAZD) was developed. HAZD has a size of 128.75 ± 11.86 nm, a drug loading ratio of 21.5 ± 2.2% and an encapsulation efficiency of 71.8 ± 1.7%. Stability, acid responsive release character, outstanding catalytic ability to generate ROS, relatively high thermal conversion efficiency up to 62.38% and spatio-temporal controllable abilities are also found within this nano-carrier. Furthermore, HAZD performed good antitumor ability in vivo with the comprehensive effects of photothermal/ chemical dynamic/ chemotherapy. The tumor growth inhibition value is 97.1% within 12 days, indicating its great potential in multi-modal synergistic cancer therapy. : Cancer remains one of the major culprits that seriously harm human health currently. With the development of materials and nanotechnology, great improvements have been made in multimodal anti-tumor strategies. However, temporal- and spatial-controllable multi-modal synergistic nanocarriers are urgently awaited for efficient and low-toxicity tumor therapy. This article proposes a spatio-temporally controllable three-modal anti-tumor strategy and designs an anti-tumor drug delivery system based on gold nanoparticles (AuNPs) and zeolite-like imidazole skeleton material (ZIF-8), which shows acid-responsive release characteristics, catalytic ability to generate ROS, relatively high thermal conversion efficiency up to 62.38%, as well as spatio-temporal controllable abilities. Moreover, it demonstrates outstanding anti-tumor ability, with a tumor growth inhibition value of 97.1% within 12 days, revealing its significant potential for future personalized and precise anti-tumor treatments.
科研通智能强力驱动
Strongly Powered by AbleSci AI